NASDAQ:YMAB Y-mAbs Therapeutics (YMAB) Stock Forecast, Price & News $8.70 -0.30 (-3.33%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$8.64▼$9.2350-Day Range$2.83▼$10.3452-Week Range$2.70▼$20.48Volume244,500 shsAverage Volume586,236 shsMarket Capitalization$380.02 millionP/E RatioN/ADividend YieldN/APrice Target$13.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Y-mAbs Therapeutics MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside57.1% Upside$13.67 Price TargetShort InterestHealthy5.46% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 5 Articles This WeekInsider TradingAcquiring Shares$981,791 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.96) to ($0.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector372nd out of 1,010 stocksPharmaceutical Preparations Industry167th out of 494 stocks 3.1 Analyst's Opinion Consensus RatingY-mAbs Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 5 buy ratings, 5 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.67, Y-mAbs Therapeutics has a forecasted upside of 57.1% from its current price of $8.70.Amount of Analyst CoverageY-mAbs Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.46% of the float of Y-mAbs Therapeutics has been sold short.Short Interest Ratio / Days to CoverY-mAbs Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Y-mAbs Therapeutics has recently decreased by 2.70%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldY-mAbs Therapeutics does not currently pay a dividend.Dividend GrowthY-mAbs Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for YMAB. Previous Next 2.5 News and Social Media Coverage News SentimentY-mAbs Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Y-mAbs Therapeutics this week, compared to 4 articles on an average week.Search Interest17 people have searched for YMAB on MarketBeat in the last 30 days. This is an increase of 42% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Y-mAbs Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $981,791.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.61% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.96% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($0.96) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Y-mAbs Therapeutics is -5.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Y-mAbs Therapeutics is -5.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioY-mAbs Therapeutics has a P/B Ratio of 3.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Y-mAbs Therapeutics (NASDAQ:YMAB) StockY-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.Read More Receive YMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address YMAB Stock News HeadlinesMay 26, 2023 | finance.yahoo.comY-mAbs Announces Presentation of GD2-SADA Study at ASCOMay 26, 2023 | finance.yahoo.comY-mAbs Announces Presentation of Naxitamab Data at ASCOMay 29, 2023 | UNKNOWN (Ad)World-Renowned Brazilian Restaurant Debuts in CanadaInvest in Debut's Exclusive Franchise of Acclaimed Brazilian Churrasco Restaurant Brand.May 24, 2023 | americanbankingnews.comBrokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Target Price at $13.13May 23, 2023 | finance.yahoo.comY-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in BrazilMay 15, 2023 | msn.comB of A Securities Maintains Y-Mabs Therapeutics (YMAB) Neutral RecommendationMay 15, 2023 | markets.businessinsider.comB of A Securities Maintains Neutral Rating for Y-mAbs Therapeutics: Here's What You Need To KnowMay 15, 2023 | markets.businessinsider.comBank of America Securities Keeps Their Hold Rating on Y-Mabs Therapeutics (YMAB)May 29, 2023 | UNKNOWN (Ad)World-Renowned Brazilian Restaurant Debuts in CanadaInvest in Debut's Exclusive Franchise of Acclaimed Brazilian Churrasco Restaurant Brand.May 15, 2023 | americanbankingnews.comY-mAbs Therapeutics (NASDAQ:YMAB) Price Target Increased to $12.00 by Analysts at Bank of AmericaMay 14, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Issued By WedbushMay 13, 2023 | finance.yahoo.comNew Forecasts: Here's What Analysts Think The Future Holds For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)May 13, 2023 | americanbankingnews.comFY2027 Earnings Forecast for Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Issued By WedbushMay 13, 2023 | americanbankingnews.comY-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Upgraded by WedbushMay 12, 2023 | msn.comWedbush Upgrades Y-Mabs Therapeutics (YMAB)May 12, 2023 | msn.comMorgan Stanley Maintains Y-Mabs Therapeutics (YMAB) Underweight RecommendationMay 11, 2023 | americanbankingnews.comNovartis (NYSE:NVS) & Y-mAbs Therapeutics (NASDAQ:YMAB) Financial ReviewMay 10, 2023 | msn.comY-mAbs gains as Wedbush upgrades after Q1 resultsMay 10, 2023 | markets.businessinsider.comAnalyst Upgrades Y-mAbs On Bullish Danyelza Sales Outlook, Improved VisibilityMay 10, 2023 | finance.yahoo.comY-mAbs Therapeutics First Quarter 2023 Earnings: Beats ExpectationsMay 10, 2023 | finance.yahoo.comQ1 2023 Y-mAbs Therapeutics Inc Earnings CallMay 9, 2023 | finanznachrichten.deY-mAbs Therapeutics, Inc: Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial GuidanceMay 8, 2023 | finance.yahoo.comY-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2023 | finance.yahoo.comY-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial GuidanceMay 7, 2023 | americanbankingnews.comY-mAbs Therapeutics (YMAB) Scheduled to Post Quarterly Earnings on MondayMay 5, 2023 | msn.comPreview: Y-mAbs Therapeutics's EarningsApril 29, 2023 | americanbankingnews.comAnalysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) PT at $11.38See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive YMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address YMAB Company Calendar Last Earnings5/08/2023Today5/29/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:YMAB CUSIPN/A CIK1722964 Webwww.ymabs.com Phone(646) 885-8505FaxN/AEmployees148Year FoundedN/APrice Target and Rating Average Stock Price Forecast$13.67 High Stock Price Forecast$27.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+57.1%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-95,570,000.00 Net Margins-98.48% Pretax Margin-98.48% Return on Equity-64.77% Return on Assets-50.27% Debt Debt-to-Equity RatioN/A Current Ratio4.78 Quick Ratio4.44 Sales & Book Value Annual Sales$65.27 million Price / Sales5.82 Cash FlowN/A Price / Cash FlowN/A Book Value$2.47 per share Price / Book3.52Miscellaneous Outstanding Shares43,680,000Free Float34,676,000Market Cap$380.02 million OptionableNot Optionable Beta0.78 Key ExecutivesThomas GadPresident, Chief Executive Officer & DirectorJoris Wiel Jan WilmsChief Operating Officer & Senior Vice PresidentBo KruseCFO, Secretary. Treasurer & Executive VPTorben Lund-HansenChief Technology Officer & Senior Vice PresidentSteen LisbyChief Scientific Officer & Senior Vice PresidentKey CompetitorsAllakosNASDAQ:ALLKDesign TherapeuticsNASDAQ:DSGNAerovate TherapeuticsNASDAQ:AVTECentessa PharmaceuticalsNASDAQ:CNTAArbutus BiopharmaNASDAQ:ABUSView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 162,752 shares on 5/18/2023Ownership: 0.447%New York State Common Retirement FundSold 18,400 shares on 5/18/2023Ownership: 0.014%Geode Capital Management LLCBought 31,351 shares on 5/16/2023Ownership: 1.517%Susquehanna International Group LLPBought 3,199 shares on 5/16/2023Ownership: 0.112%Susquehanna Fundamental Investments LLCSold 1,718 shares on 5/16/2023Ownership: 0.094%View All Insider TransactionsView All Institutional Transactions YMAB Stock - Frequently Asked Questions Should I buy or sell Y-mAbs Therapeutics stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" YMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YMAB, but not buy additional shares or sell existing shares. View YMAB analyst ratings or view top-rated stocks. What is Y-mAbs Therapeutics' stock price forecast for 2023? 12 Wall Street analysts have issued 12-month price targets for Y-mAbs Therapeutics' shares. Their YMAB share price forecasts range from $4.00 to $27.00. On average, they anticipate the company's share price to reach $13.67 in the next twelve months. This suggests a possible upside of 57.1% from the stock's current price. View analysts price targets for YMAB or view top-rated stocks among Wall Street analysts. How have YMAB shares performed in 2023? Y-mAbs Therapeutics' stock was trading at $4.88 at the beginning of 2023. Since then, YMAB stock has increased by 78.3% and is now trading at $8.70. View the best growth stocks for 2023 here. When is Y-mAbs Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our YMAB earnings forecast. How were Y-mAbs Therapeutics' earnings last quarter? Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) posted its quarterly earnings data on Monday, May, 8th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.16. The company earned $20.30 million during the quarter, compared to analysts' expectations of $15.55 million. Y-mAbs Therapeutics had a negative net margin of 98.48% and a negative trailing twelve-month return on equity of 64.77%. Y-mAbs Therapeutics's revenue for the quarter was up 93.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.64) earnings per share. What other stocks do shareholders of Y-mAbs Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN). When did Y-mAbs Therapeutics IPO? (YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager. What is Y-mAbs Therapeutics' stock symbol? Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB." Who are Y-mAbs Therapeutics' major shareholders? Y-mAbs Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.41%), State Street Corp (1.75%), Geode Capital Management LLC (1.52%), AIGH Capital Management LLC (0.98%), Acadian Asset Management LLC (0.91%) and Charles Schwab Investment Management Inc. (0.54%). Insiders that own company stock include Biotech Aps Wg, Bo Kruse, David N Gill, Johan Wedell-Wedellsborg, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah. View institutional ownership trends. How do I buy shares of Y-mAbs Therapeutics? Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Y-mAbs Therapeutics' stock price today? One share of YMAB stock can currently be purchased for approximately $8.70. How much money does Y-mAbs Therapeutics make? Y-mAbs Therapeutics (NASDAQ:YMAB) has a market capitalization of $380.02 million and generates $65.27 million in revenue each year. The company earns $-95,570,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. How many employees does Y-mAbs Therapeutics have? The company employs 148 workers across the globe. How can I contact Y-mAbs Therapeutics? Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The official website for the company is www.ymabs.com. The company can be reached via phone at (646) 885-8505 or via email at info@ymabs.com. This page (NASDAQ:YMAB) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.